Oral Mucositis Therapeutic Landscape Explored by ProGrow Pharma Partners in Its New Report Recently Added at MarketPublishers.com
17 Nov 2017 • by Natalie Aster
LONDON – Whilst the mechanism oral mucositis (OM) is well established, there are very few targeted drugs or therapeutic options currently available to patients. If untreated it could be even life threatening (sepsis) and palliative care offer just temporary relief. New therapies could help to cut associated costs and also improve the quality of life. There is a strong need for systematic management of OM triggered by anti-neoplastic protocols.
Presently, around 800 thousand patients worldwide suffer from mucositis during cancer therapy each year, and this figure is constantly increasing. Appr. 80-100% of head and neck cancer patients develop Ulcerative OM.
The incidence of OM is very high in the Asia region, especially in China and India, given local lifestyle and high smoking prevalence.
New research report “Therapeutic Class Report: Oral Mucositis” elaborated by ProGrow Pharma Partners presents a close look at the world’s market for oral mucositis (OM) therapeutics. It gives an overview of the unmet needs, identifies the emerging opportunities across different geographical markets, provides a detailed pipeline analysis and reviews the currently available and anticipated to be launched drugs. Beside, this research study contains a details disease overview, reviews top companies engaged in the development of OM drugs, sheds light on the current scenario across various regional markets and also evaluates the market’s growth potential.
For other research studies prepared by this publisher follow ProGrow Pharma Partners page at MarketPublishers.com.